<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144439">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01674985</url>
  </required_header>
  <id_info>
    <org_study_id>MST/MDS-307PLAH-ASH</org_study_id>
    <nct_id>NCT01674985</nct_id>
  </id_info>
  <brief_title>Microtransplantation With Decitabine and Cytarabine Improves Patient Outcomes in Myelodysplastic Syndromes</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Affiliated Hospital of the Chinese Academy of Military Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Second Artillery General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Affiliated Hospital of the Chinese Academy of Military Medical Sciences</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether infusion of G-CSF mobilized
      HLA-mismatched peripheral blood stem cells (G-PBSC) combining decitabine and cytarabine
      chemotherapy can improve outcomes in myelodysplastic syndromes (MDS) patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>complete remission</measure>
    <time_frame>six months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>three years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>overall survival</measure>
    <time_frame>three years</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Decitabine and cytarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>decitabine 25-30 mg/m2 daily for 4 days with cytarabine 100-150 mg/m2 daily for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Microtransplantation</intervention_name>
    <description>Infusion of G-CSF mobilized  HLA-mismatched peripheral blood stem cells (G-PBSC)</description>
    <arm_group_label>Decitabine and cytarabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients 10 to 90 years old with primary or treatment-related MDS or chronic
             myelomonocytic leukemia;

          -  International Prognostic Scoring System(IPSS) intermediate-1,intermediate-2,or high
             risk;

          -  bone marrow blasts &gt; 11% or &lt;= 10% and poor cytogenetics;

          -  lack of an HLA-identical donor;

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2;

          -  adequate cardiac and hepatorenal functions.

        Exclusion Criteria:

          -  have an HLA-identical donor
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sheng Hui Ai, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Affiliated Hospital of Academy of Military Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>sheng hui ai, M.D</last_name>
    <phone>86-01-66947126</phone>
    <email>huishengai@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>zheng dong, M.M</last_name>
    <phone>86-01-66947130</phone>
    <email>dongzheng307@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Affiliated Hospital of Academy of Military Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>sheng hui ai, M.D</last_name>
      <phone>86-01-66947126</phone>
      <email>huishengai@163.com</email>
    </contact>
    <contact_backup>
      <last_name>zheng dong, M.M</last_name>
      <phone>86-01-66947130</phone>
      <email>dongzheng307@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Xun Kai Hu, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Guo M, Hu KX, Yu CL, Sun QY, Qiao JH, Wang DH, Liu GX, Sun WJ, Wei L, Sun XD, Huang YJ, Qiao JX, Dong Z, Ai HS. Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients. Blood. 2011 Jan 20;117(3):936-41. Epub 2010 Oct 21.</citation>
    <PMID>20966170</PMID>
  </reference>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 27, 2013</lastchanged_date>
  <firstreceived_date>August 25, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Decitabine</keyword>
  <keyword>microtransplantation</keyword>
  <keyword>myelodysplastic syndromes</keyword>
  <keyword>chemotherapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Decitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
